Floatz logo

NEPENTHE

Degenerative Disc Disease

Brigham and Women's HospitalSmall moleculePhase 4 / ApprovedDormant
BB
68/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
54/ 100
Competitive Position
89/ 100

Competitive context

9 Active assets in the Degenerative Disc Disease cohort.

Asset / SponsorPhaseRating
Oxycodone
Brigham and Women's Hospital
Phase 4BB
Pentoxifylline
St Joseph University, Beirut, Lebanon
Phase 4BB
IBUPROFEN
St Joseph University, Beirut, Lebanon
Phase 4BB
Rexlemestrocel-L
Mesoblast, Ltd.
Phase 3BB
AUTOLOGOUS CONDITIONED PLASMA
Allmed Medical Center
Phase 2BB

View all 15 →

Same molecule, other indications

NEPENTHE is also rated in:

PainDormant
BBB
Indicative ·
77 / 100
View asset →
cancer of unknown primary siteDormant
BBB
Indicative ·
75 / 100
View asset →
chronic pain syndromeDormant
BBB
Indicative ·
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →